JP Morgan raised Syndax's price target to $41, citing strong early Revuforj sales and physician confidence in its use for acute leukemias and NPM1 AML.

This class of biologic may work particularly well in blood cancers with mutated nucleophosmin 1 (NPM1). The antibody may be combined with a delta opioid receptor (DOR) inhibitor and/or a menin ...

It comes a few days after the company's shares came under pressure from the results of a phase 1/2 trial of Revuforj in relapsed or refractory mutant NPM1 acute myeloid leukaemia (AML), a follow ...